ABOUT US

RESPONSE SCIENTIFIC, INC.® (RSI) is a Research Biotechnology Corporation. RSI’s mission is to improve lives through innovative medical research and biomedical engineering leading to revolutionary new products and delivery systems for the general maintenance of health and the treatment and prevention of disease in humans and animals.

The Company has maintained a close working relationship with a team of the country’s leading biochemists and biomedical engineers for more than a decade. Currently, the Company is entering the commercialization stage for FDA-regulated and non-regulated healthcare products which represent a multibillion-dollar business.

The Company has recently trademarked the name Aegis Abuse Deterrence to describe the portion of its technology developed to improve the delivery and safety of drugs with a history of addiction potential and illicit manipulation. These include opioids, antidepressants, stimulants and OTC allergy/cold medications that contain pseudoephedrine.

OUR TECHNOLOGY

The Company has optioned the exclusive worldwide rights for a novel patent pending technology titled Modified Alginate Hydrogels for Therapeutic Agents (USPTO Pending #15/606/769 & PCT Pending # PCT/US/17/34748) and a second filing titled Modified Carbohydrates, Compositions Comprising the Same, and Methods of Making and Using the Same (PCT Pending # PCT/US/17/40283).

The technology revolutionizes how prescription and non-prescription medications, veterinary medicines, probiotics, and dietary supplements are delivered orally while being protected from damaging stomach acids and enzymatic actions. This technology also creates an entirely new mechanism of time release. Where maximum time release is required the hydrogels can be coated with a naturally derived mucoadhesive polymer.

Once a drug is embedded in the hydrogel it is inseparable from the hydrogel, thereby eliminating the concentration, dilution, or nasal inhalation of the powdered drug. This is critically important when dealing with controlled substance drugs such as opioids and morphine derivatives, antidepressants and stimulants.

The patent filing describes the unique chemistry of the hydrogel technology as well as a broad range of potential uses and applications. For example, the hydrogels can be used to deliver prescription and non-prescription pain relief medications that often cause nausea and stomach upset when released in the stomach.

The hydrogels can be supplied in RSI’s patent pending straw-like pouches (see Abuse Deterrent Packaging Technology) and can be mixed wherein fast acting hydrogels, and slow extended time release hydrogels, are contained in the same pouch proportioned to the specific drug application.

The tasteless, colorless, and odorless hydrogels can be delivered in an edible form for drug delivery to humans and animals, in hermetically sealed disposable pouch style straws, or placed in standard capsules. If desired, particularly in pediatric and elderly applications, the pouches can also contain flavor crystals.

The hydrogels are small enough (300-500um) that delivery can be readily accomplished where water is contaminated or not available at all. They are easily swallowed by saliva alone.

An important step in improved abuse-deterrent technology for drug products such as opioids, antidepressants and stimulants, RSI’s hydrogel beads are supplied in patent pending* individual dose, straw-like pouches that are sealed and clearly marked with coded serial identifiers (CSIs). The hydrogel beads can also be provided in standard capsules, however, standard capsules do not provide space for the placement of millions of different individual coded serial identifiers.

The coded serial identifier pouches provide critical information such as the name of the prescribing physician, along with tracking information including the date and location of manufacturer, distributor and retail pharmacy name and address.

These individual pouches are then placed in factory-sealed and coded bottles provided to the pharmacy in frequently prescribed quantities.  The pharmacy adheres their label to the unopened factory bottle. The pharmacy does not dispense the doses from a large bottle and handle individual dose pouches. This eliminates another weak link in the distribution chain.

This packaging technology serves as a disincentive for practitioners who overprescribe opioids or other addictive medications.

*”Imprinted Medical Packages and Methods of Making and Using the Same” (Pending #US/62,555,168)

The patent pending hydrogel technology delivers the contents of drugs and medicines after reaching the small intestine, thus allowing the medicine to move through the stomach unharmed and eliminating undesirable side effects some medicines can cause. The nontoxic hydrogel component chemistry has no effect on drugs and medicines being delivered.

There are numerous embodiments listed in the patent filings. Depending on the application, and the specific modification utilized, the modified alginate hydrogels function differently.

The hydrogels can be modified to increase or decrease the speed at which they move through the small intestine and diffuse their contents. Where maximum time release is required the hydrogels can be coated with a naturally derived mucoadhesive polymer in order to slow the diffusion process. This polymer coating can be of varying thicknesses thereby controlling the diffusion rate for a specific application.

Aspirin (Acetylsalicylic Acid) and other non-prescription pain relief medications can cause upset stomach, nausea, and stomach ulcers, which is largely responsible for Tylenol (acetaminophen) being created and becoming the non-prescription medication of choice by most physicians. RSI’s hydrogel technology eliminates the problems associated with aspirin and its effect on the stomach. Tylenol (acetaminophen), on the other hand, has been known to cause liver problems if taken too frequently.

The chemistry of the hydrogel enhances shelf life longevity by acting as a barrier against oxidation and degradation. The hermetically sealed individual pouches or straws act as a second line of defense against oxidation, a critical feature for emergency medications that must be stored/stockpiled, such as potassium iodide, a prophylactic for radioactive iodine exposure, typically from nuclear reactor leakage or contamination.

A wide variety of medicines must be given to large and small animals on a regular basis, and due to the taste or smell of the medicine, animals often reject it. Cats in particular are not easily given pills of any kind.

In addition, equine dewormers are required to be administered 3-4 times yearly in order to maintain good health and performance. These dewormers are currently delivered in a paste form placed in the back of the horse’s mouth using a syringe-type device. This delivery technique can be awkward and problematic for the handler. It is also inefficient because the horse spits out an unknown amount of paste making the actual amount given questionable.

RSI’s patented hydrogels, which are tasteless and odorless, can contain a wide range of medications and dietary supplements, and be embedded in a “treat” or other food form palatable to the animal. This hydrogel technology is adjustable to accommodate different drug dosages based on veterinary recommendations related to animal weight.

Probiotics are living micro-organisms essential to our health and well-being. The field of probiotics is advancing in the scientific and medical communities, and consumer acceptance has grown exponentially. The future growth of probiotic sales in this country and worldwide is projected to be in double digits and in the billions of dollars. Probiotics are defined as living micro-organisms that naturally reside in the human intestine. Scientific research has recently established that they are vital to a properly functioning immune system and to overall physical well-being and mental health. Through a variety of factors such as disease or the use of antibiotics, the normal balance of “good” versus “bad” bacteria in the intestine can be damaged or seriously impaired, and can be fatal if not successfully treated. These imbalances in the microbiome of the intestine have been shown to have other profound effects. These imbalances can be successfully addressed and treated through the use of probiotics.

The major problem with all probiotics manufactured in the world today is most are unable to survive in the acidic pH of the stomach, and cannot fulfill their goal of colonizing in the gut, and do not reach the small intestine alive. The European Food Safety Authority (EFSA), which is the equivalent to our FDA, does not allow for the word “probiotic” to be used in describing these bacteria unless manufacturers can prove the bacteria are alive when taken by the consumer. Consequently, there are currently no “probiotic labeled” products on the market in EU countries. This creates another opportunity for RSI’s hydrogel technology.

Given the distinct advantages of RSI’s new delivery system, live probiotics can be delivered to the small intestine without being destroyed by stomach acids. This particular application holds the promise of a significant increase in health benefits, as well as a clear marketing advantage over existing probiotic manufacturers worldwide.